Is Coral Labs. overvalued or undervalued?

As of 20 October 2025, Coral Labs has moved from an attractive to a very attractive valuation grade. The company is currently undervalued, with a PE ratio of 9.57, a Price to Book Value of 0.88, and an EV to EBITDA ratio of 4.13. In comparison to its peers, Coral Labs stands out with a significantly lower PE ratio than Sun Pharma, which is considered expensive at 35.32, and Divi's Lab, which is very expensive at 76.2.
Despite recent stock performance lagging behind the Sensex, with a year-to-date return of -35.11% compared to the Sensex's 7.97%, the underlying financial metrics suggest that Coral Labs presents a compelling investment opportunity. The company's ROCE of 14.67% and ROE of 9.18% further reinforce its strong operational efficiency relative to its peers.